Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Dalgarno

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
SRC inhibitors in metastatic bone diseaseBrendan F Boyce, Lianping Xing, Zhenqiang Yao, et al.
Chemical Biology & Drug Design|December 2, 2010
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistanceTianjun Zhou, Lois Commodore, Wei-Sheng Huang, et al.
Biopolymers|March 3, 2004
Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistryRaji Sundaramoorthi, Noriyuki Kawahata, Michael G Yang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2004
Differences in F36VMpl-based in vivo selection among large animal modelsRobert E Richard, R Angelo De Claro, James Yan, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2006
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistanceMohammad Azam, Valentina Nardi, William C Shakespeare, et al.
Journal of Medicinal Chemistry|December 25, 2015
Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug DiscoveryStephan G Zech, Anna Kohlmann, Tianjun Zhou, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseasesYihan Wang, Chester A Metcalf, William C Shakespeare, et al.
Cancer Research|September 5, 2006
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinomaLiz Y Han, Charles N Landen, Jose G Trevino, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analoguesRaji Sundaramoorthi, William C Shakespeare, Terence P Keenan, et al.
Journal of Medicinal Chemistry|January 11, 2013
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitorsAnna Kohlmann, Stephan G Zech, Feng Li, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
SRC inhibitors in metastatic bone diseaseBrendan F Boyce, Lianping Xing, Zhenqiang Yao, et al.
Chemical Biology & Drug Design|December 2, 2010
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistanceTianjun Zhou, Lois Commodore, Wei-Sheng Huang, et al.
Biopolymers|March 3, 2004
Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistryRaji Sundaramoorthi, Noriyuki Kawahata, Michael G Yang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2004
Differences in F36VMpl-based in vivo selection among large animal modelsRobert E Richard, R Angelo De Claro, James Yan, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2006
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistanceMohammad Azam, Valentina Nardi, William C Shakespeare, et al.
Journal of Medicinal Chemistry|December 25, 2015
Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug DiscoveryStephan G Zech, Anna Kohlmann, Tianjun Zhou, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseasesYihan Wang, Chester A Metcalf, William C Shakespeare, et al.
Cancer Research|September 5, 2006
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinomaLiz Y Han, Charles N Landen, Jose G Trevino, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analoguesRaji Sundaramoorthi, William C Shakespeare, Terence P Keenan, et al.
Journal of Medicinal Chemistry|January 11, 2013
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitorsAnna Kohlmann, Stephan G Zech, Feng Li, et al.
Pageof 3